How do you develop a therapeutic vaccine that patients and health systems will value?
A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
Bringing a nuanced understanding of reimbursement systems and market influencers, Shift Health captured critical perspectives on disease burden and priority; the value and limitations of existing treatment options; the potential role of a therapeutic vaccine in disease management by patient segment; and pricing/value considerations central to health systems’ willingness to pay. The Shift Health team translated these insights into incisive, evidence-based recommendations to align product characteristics with payer and patient needs.
Based on Shift Health’s advice, the company altered the target product profile and clinical development plans, accelerating time-to-market and maximizing future revenues.
Shift Health has provided the precedent-setting, entrepreneurial framework to enable strategy development and align international stakeholders on important global public health matters.
DR. JIM TARTAGLIA VP R&D, Sanofi Pasteur